Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Screening for Lung Cancer With Low-Dose Computed Tomography
582
Zitationen
14
Autoren
2021
Jahr
Abstract
Screening high-risk persons with LDCT can reduce lung cancer mortality but also causes false-positive results leading to unnecessary tests and invasive procedures, overdiagnosis, incidental findings, increases in distress, and, rarely, radiation-induced cancers. Most studies reviewed did not use current nodule evaluation protocols, which might reduce false-positive results and invasive procedures for false-positive results.
Ähnliche Arbeiten
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
2011 · 10.844 Zit.
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 · 9.966 Zit.
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 · 8.213 Zit.
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
2015 · 6.488 Zit.
Deep Convolutional Neural Networks for Computer-Aided Detection: CNN Architectures, Dataset Characteristics and Transfer Learning
2016 · 5.733 Zit.